Nonetheless, although the dual treatment of a PI3K/Akt inhibitor and a cell cycle inhibitor demonstrated synergistic effects against preclinical breast cancer and head and neck squamous cell carcinoma {Remer, 2020 #2848;Teo, 2017 #2849}, clinical use of this combination has resulted in unexpected toxicity in breast cancer patients {Tolaney, 2021 #2850}. The gene discussed is AKT1; the disease is breast cancer.